Carbelan, or CBZ, is an anticonvulsant medication and a mood-stabilizing agent. It acts by decreasing the amount of excitement in the brain and is used for epilepsy and the treatment of bipolar disorders. Carbelan is effective in controlling seizures by blocking specific brain impulses. It is also used to treat ADD (Attention Deficit Disorder), ADHD (Attention Deficit Hyperactive Disorder), and schizophrenia (a psychiatric condition).
Used alone or combined with other seizure medications, Carbelan is used to calm manic episodes where the patient exhibits extreme mood swings, mixed episodes of mania and depression, and other abnormal moods.
Carbelan can be used in the treatment of trigeminal neuralgia, a condition causing severe pain in the facial nerves. Carbelan shifts nerve impulses from the affected facial nerves to ease the pain associated with this condition.
Carbelan is also used to treat mental illnesses including depression, post-traumatic stress disorder, withdrawal from medication and alcohol addictions, restless legs syndrome, diabetes insipidus and a children's disease called chorea.
Patients with bone marrow suppression, porphyria (a blood disorder) and atrioventricular block (a severe heart block problem) should avoid Carbelan since the medication may make their conditions worse. Patients taking antidepressant medications including amitriptyline (Elavil), desipramine (Norpramin), imipramine (Trofranil), or nortriptyline (Pamelor) should avoid Carbelan to prevent adverse interactions between the medications.
Other medications that interact negatively with this medication include cold and allergy medicines, pain relievers, sleeping pills, muscle relaxants, antidepressants like isocarboxazid (Marplan) and phenelzine (Nardil), and anti-anxiety medicines like tranylcypromine (Parnate). Patients taking selegiline, a medication to treat early-stage Parkinson's disease and senile dementia, should avoid Carbelan.
Patients should not consume alcoholic beverages while taking this medication to avoid the risk of seizures. Patients need to let their physician know if they are taking any prescription or over-the-counter medications, including vitamin, mineral or herbal supplements before starting Carbelan treatment.
Carbelan is classified in pregnancy category D by the FDA. This means that this medication may harm an unborn baby. Patients who are pregnant, plan to become pregnant or become pregnant during treatment should talk with their physician about the risks involved. Since this medication can also be passed on through breast milk and harm nursing infants, patients should refrain from breastfeeding while taking this medication. Carbelan may decrease the effectiveness of hormone-based birth control pills. Patients need to talk with their physician regarding birth control before beginning treatment with this medication. Carbelan may lower the body's infection-fighting blood cells. Patients taking this medication should have their blood and liver functions checked regularly.
Other known side effects include drowsiness, dizziness or headaches, vomiting, anxiety, constipation or diarrhea, heartburn, dry mouth, back pain, and impaired motor coordination or unsteadiness of movement. In rare cases, Carbelan has been known to cause cardiac arrhythmias, blurred eyesight or double vision, and some loss of blood cells or platelets.
Severe known side effects including allergic rashes, breathing difficulties, confusion, depression, suicidal thoughts, chest pain, black or tarry stools, jaundice, and losing touch with reality are very rare, but are considered serious and require immediate medical attention.
Carbelan is sold under many brand names, including Tegretol, Epitol, Equetro, Finlepsin, Sirtal, Stazepine, Talesmin, Teril, Timonil, Trimonil, and Epimaz. The medication comes in tablet form, chewables, extended-release tablets and capsules, and a liquid (suspension).
Patients should not stop taking the medication without consulting their physician first. Suddenly stopping Carbelan may cause an increase in the number of seizures and produce other unpleasant side effects.
Carbelan has the following structural formula:
• Molecular formula of carbelan is C15H12N2O
• Chemical IUPAC Name is 5H-dibenz[b,f]azepine-5-carboxamide
• Molecular weight is 236.269 g/mol
• Carbelan available : 100mg tablets, 100mg/5ml suspension, 200mg tablets
©2007-2017 Medicalook.com All rights reserved